Zimmer Biomet Launches New Foot and Ankle Fixation System to Address Complex Small Bone Reconstruction

(Warsaw, Ind.) January 20, 2026 - Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, together with its wholly owned subsidiary Paragon 28, today announced the commercial launch of the Brachiator™ Mini-Rail External Fixation System, a platform designed for precise, multi-planar correction, rapid construct assembly, and workflow efficiency for the correction of bone deformities and stabilization of fractures of the foot and ankle.

The Brachiator System expands the Company's external fixation portfolio capabilities into forefoot and the midfoot, where millimeters matter. Engineered with extensive surgeon feedback, the system combines compact design, universal pin compatibility and intuitive clamp mechanics to support a wide range of procedures.

"Developed in close collaboration with leading surgeons, the Brachiator Mini-Rail System was purpose-built to support bone deformity correction and fracture stabilization of the foot and ankle - including metatarsal lengthening and shortening and 1^st MPJ distraction - where precision down to the millimeter can determine outcomes," said Albert DaCosta, Global President of Foot and Ankle for Zimmer Biomet. "This technology empowers surgeons with versatile fixation for complex cases while prioritizing efficiency and workflow optimization. It also underscores our broader commitment to tackling health care's most pressing challenges and elevating the standard of care across musculoskeletal health."

Where conventional mini fixators rely on rigid, fixed-angle clamps - or require mid-procedure construct teardown to achieve adequate reduction - the Brachiator System introduces built-in, in-plane and out-of-plane rotational control. This enables surgeons to perform fine, multi-axis reduction even after pins are placed. The compact rail and carriage design maintains a ≥2 cm soft-tissue-friendly profile above the skin surface, which is designed to support patient tolerance and postoperative management.¹

For more information on Zimmer Biomet's comprehensive foot and ankle fixation portfolio, visit: https://paragon28.com/external-fixation-systems/.

About Zimmer Biomet

Zimmer Biomet is a global medical technology leader with a comprehensive portfolio designed to maximize mobility and improve health. We seamlessly transform the patient experience through our innovative products and suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence.

With 90+ years of trusted leadership and proven expertise, Zimmer Biomet is positioned to deliver the highest quality solutions to patients and providers. Our legacy continues to come to life today through our progressive culture of evolution and innovation.

For more information about our product portfolio, our operations in 25+ countries and sales in 100+ countries or about joining our team, visit www.zimmerbiomet.com or follow on LinkedIn at www.linkedin.com/company/zimmerbiomet or X at www.x.com/zimmerbiomet.

Cautionary Statement Regarding Forward-Looking Statements

This news release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning Zimmer Biomet's expectations, plans, prospects, and product and service offerings, including new product launches and potential clinical successes. Such statements are based upon the current beliefs and expectations of management and are subject to significant risks, uncertainties and changes in circumstances that could cause actual outcomes and results to differ materially. For a list and description of some of such risks and uncertainties, see Zimmer Biomet's periodic reports filed with the U.S. Securities and Exchange Commission (SEC). These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in Zimmer Biomet's filings with the SEC. Forward-looking statements speak only as of the date they are made, and Zimmer Biomet disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Readers of this news release are cautioned not to rely on these forward-looking statements, since there can be no assurance that these forward-looking statements will prove to be accurate. This cautionary statement is applicable to all forward-looking statements contained in this news release.

_{1. Data on file with Paragon 28}